Home/Pipeline/IP-001 + Tumor Ablation

IP-001 + Tumor Ablation

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Immunophotonics

About Immunophotonics

Immunophotonics is developing a platform based on a proprietary glycan polymer (IP-001) that enhances antigen capture and immune system activation, with an initial focus on oncology. The company's strategy involves using IP-001 in combination with standard tumor ablation techniques to convert a localized procedure into a systemic immunotherapy, potentially improving outcomes for solid tumors. Founded in 2010 and based in St. Louis, the private company is advancing its lead candidate through clinical trials while exploring platform applications to enhance other immunotherapies like checkpoint inhibitors.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed